Physicians' Academy for Cardiovascular Education

PCSK9: the new lipid target in preventive cardiology?

ESC Amsterdam, August 31, 2013

Oct. 4, 2013

The symposium PCSK9: the new lipid target in preventive cardiology? ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013.

Educational objectives

  • Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
  • Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
  • Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
  • Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk

Familial Hypercholesterolemia: Why are we not reaching goals in these patients?
John Kastelein, Academic Medical Center, Amsterdam, Netherlands

Start videopresentation




PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c
Gilles Lambert, University of Nantes Medical School, Nantes, France

Start videopresentation




Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?
Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, USA

Start videopresentation




The roadmap of PCSK9 inhibitors towards the clinic: An overview of current development programs & outcome studies
Henry Ginsberg, Columbia University Medical Center, New York

Start videopresentation



The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: